New hope to slow advanced throat cancer

NCT ID NCT03581786

Summary

This study tested if adding a new immunotherapy drug called toripalimab to standard chemotherapy could better control advanced or returning nasopharyngeal cancer. About 289 patients with this type of throat cancer were randomly assigned to receive either the new drug combination or chemotherapy with a placebo. The main goal was to see if the new combination could slow the cancer's progression and extend patients' lives compared to chemotherapy alone.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC NPC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    Guangzhou, Guangdong, 510095, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangzhou, 130012, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangzhou, 515031, China

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100021, China

  • Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital

    Taoyuan District, 333, Taiwan

  • China Medical University Hospital

    Taichung, 404, Taiwan

  • Fudan University Cancer Hospital

    Shanghai, Shanghai Municipality, 200032, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, 350000, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, 350000, China

  • Hainan General Hospital (Hainan Province People's Hospital)

    Haikou, Hainan, 570311, China

  • Hebei Oncology Hospital

    Shijiazhuang, Hebei, 50011, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Jiangsu Oncology Hospital

    Nanjing, Jiangsu, 210000, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, 330029, China

  • Liuzhou Worker's Hospital

    Liuchow, Guangxi, 545000, China

  • Nanfang Hospital

    Guangzhou, Guangdong, 510515, China

  • National Cancer Centre

    Singapore, 169610, Singapore

  • National Cheng Kung University Hospital

    Tainan, 704, Taiwan

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, 200080, China

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, 518020, China

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, 510060, China

  • TaiChung Veterans General Hospital

    Taichung, 40705, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 112, Taiwan

  • Tan Tock Seng Hospital

    Singapore, 308433, Singapore

  • The Affiliated Cancer Hospital of Guizhou Medical University

    Guiyang, Guizhou, 550000, China

  • The Fifth Affiliated Hospital Sun Yat-Sen University - Medical Oncology

    Zhuhai, Guangzhou, 519000, China

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, 530021, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, 410011, China

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & TechnologyTongji Hospital

    Wuhan, Hubei, 430030, China

  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, 430023, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

Conditions

Explore the condition pages connected to this study.